• Actinogen receives $1.9m R&D tax incentive rebate from ATO for FY2025
• Total RDTI rebate for FY2025 now $7.4m
• Rebate supports Actinogen's Alzheimer's phase 2b/3 clinical trial

Actinogen Medical has received a further $1.9m research and development tax incentive (RDTI) rebate from the Australian Tax Office (ATO) relating to overseas R&D expenditure incurred in the 2025 financial year. This additional rebate, when combined with the initial $5.5m RDTI rebate received in October 2025, brings the total RDTI rebate for FY2025 to $7.4m. The RDTI is an important source of funding for Actinogen as it rapidly approaches key milestones in its Alzheimer's disease phase 2b/3 clinical trial, known as XanaMIA. Last week, the trial's independent Data Monitoring Committee provided a positive recommendation for the trial to continue to its conclusion after a safety and efficacy futility review. Topline final results are anticipated in November 2026. Actinogen is developing its lead compound, Xanamem, as a novel therapy for Alzheimer's disease and other neurological and neuropsychiatric conditions associated with dysregulated brain cortisol. The company has studied Xanamem in approximately 400 volunteers and patients across eight clinical trials, demonstrating a promising safety profile and clinical activity in patients with depression and Alzheimer's disease.